All In Biotech

NDA 205874 · Keryx Biopharms

Auryxia

Ferric Citrate · Oral

Last checked: Nov 20, 2026Latest source record: Jan 19, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Sep 5, 2014

Approved uses

2

Original approval plus efficacy supplements

Registered trials

553

145 Phase 3, 57 recruiting

FAERS reports

2,203

775 serious, 261 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 29, 2026.

Auryxia is a phosphate binder indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis. ( 1 ) Auryxia is an iron replacement product indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis. ( 1 ) 1.1 Hyperphosphatemia in Chronic Kidney Disease on Dialysis Auryxia is indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis. 1.2 Iron Deficiency Anemia in Chronic Kidney Disease Not on Dialysis Auryxia is indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis.

Mechanism: Hyperphosphatemia in Chronic Kidney Disease on Dialysis Ferric iron binds dietary phosphate in the GI tract and precipitates as ferric phosphate. This compound is insoluble and is excreted in the stool. By binding phosphate in the GI tract and decreasing absorption, ferric citrate lowers the phosphate concentration in the serum. Iron Deficiency Anemia in Chronic Kidney Disease Not on Dialysis Ferric iron is reduced from the ferric to the ferrous form by ferric reductase in the GI tract. After transport through the enterocytes into the blood, oxidized ferric iron circulates bound to the plasma...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • AURYXIA · FERRIC CITRATE EQ 210MG IRON · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Ferric" as an intervention, any sponsor and status, largest first.

All 553 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea310
  • serum ferritin increased228
  • transferrin saturation increased169
  • faeces discoloured118
  • death112
  • constipation83
  • nausea71
  • drug ineffective69
  • vomiting65
  • chronic kidney disease59
  • end stage renal disease58
  • pruritus55

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20111
20142
2015131
2016176
2017408
2018313
2019252
2020276
2021233
2022130
202362
202495
202585
202638

Recalls

4 FDA enforcement reports for this application.

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

  • Dec 9, 2020 · Class II · Terminated

    CGMP Deviations

  • Jul 10, 2020 · Class II · Terminated

    cGMP deviations: Lots recalled were not manufactured in conformance with the FDA-approved manufacturing process for Auryxia.

  • Dec 12, 2017 · Class III · Terminated

    Presence of Foreign Substance: Reports have been received of damaged StripPax packets containing silica gel desiccant potentially allowing the silica gel granules to make contact with Auryxia tablets in the bottle.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Auryxia (Ferric Citrate)

2024 spending

$132M

Beneficiaries

17,163

72,567 claims

Per beneficiary

$7,664

$7.24 per unit

View as table
YearSpending
2020$196,402,947
2021$199,110,901
2022$194,683,928
2023$182,627,699
2024$131,543,849

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 788 on PubMed

Sponsor: Keryx Biopharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.